

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.)

Tel. 0731-2723016; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2723017

Date: 25th March, 2025

To, The Secretary (DCS/Compliance), Corporate Relationship Department, BSE Limited (DCS/Compliance) Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary (Listing/Compliance), National Stock Exchange of India Ltd., Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400051
---	--

SUBJECT: INTIMATION OF CLOSURE OF TRADING WINDOW

REFERENCE: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE SCRIP CODE 524396; NSE SYMBOL: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

This is with reference to the ***BSE Circular Ref No. LIST/COMP/01/2019-20 and NSE Circular Ref No. NSE/CML/2019/11 dated 02.04.2019***, we wish to inform you that in terms of the Company's Code of Conduct to regulate, monitor and report trading in Company's Securities by Insiders framed under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the securities of the Company shall remain closed for all Designated Persons, their immediate relatives and connected persons (as defined in the Code) w.e.f. ***Tuesday, April, 01, 2025*** for the purpose of consideration of Audited Financial Results for the Quarter and Financial Year ended March 31, 2025.

This is further informed that the Company has also complied with the requirements of Securities and Exchange Board of India (SEBI) Circular No. SEBI/HO/ISD/ISD-SEC-4/P/CIR/2022/107 dated August 5, 2022 and SEBI/HO/ISD/ISD-PoD-2/P/CIR/2023/124 dated July 19, 2023, regarding Trading Window Closure period under Clause 4 of Schedule B read with Regulation 9 of SEBI (Prohibition of Insider Trading) Regulations, 2015 ("PIT Regulations") framework for restricting trading by Designated Persons ("DPs") by freezing PAN at security level.

The Trading Window shall open 48 hours after the Audited Financial Results for the quarter and Financial Year ended March 31, 2025, become generally available i.e. declaration of these Results to the Stock Exchange.

Further, we are submitting the above said information in XBRL mode (excel template provided by Exchanges) along with the submission in PDF mode within prescribed time.

The date of Board Meeting for the purpose of consideration of Audited Financial Results for the quarter and financial year ended March 31, 2025 would be intimated in due course.

This is for your information and further dissemination.

Thanking you,

Yours Faithfully,

FOR, BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

PAVAN SINGH RAJPUT
CHIEF FINANCIAL OFFICER